Irbesartan/Hydrochloorthiazide Sandoz

Irbesartan, the active ingredient in Irbesartan/Hydrochloorthiazide Sandoz, is an angiotensin II receptor blocker presented as a tablet for oral use. It lowers blood pressure in adults with hypertension. The formulation also contains hydrochlorothiazide, a thiazide diuretic that enhances blood‑pressure control by increasing urinary sodium loss.

GNH USA supplies Irbesartan/Hydrochloorthiazide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to WHO‑GMP standards and provides regulatory documentation to support import and distribution in multiple markets.

Irbesartan/Hydrochlorothiazide is indicated for hypertension, a condition characterized by elevated arterial pressure.

- Hypertension (essential): reduces systolic and diastolic blood pressure to target levels. - Secondary hypertension: assists in controlling blood pressure when the elevation is due to an underlying disorder. - High blood pressure: improves overall cardiovascular risk profile by maintaining recommended pressure thresholds.

Like all antihypertensive combinations, Irbesartan/Hydrochlorothiazide may cause adverse reactions.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Increased urination: due to the diuretic component. - Electrolyte imbalance (low potassium): may cause muscle cramps or weakness. - Fatigue: feeling of reduced energy.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Acute kidney injury: sudden decline in renal function. - Significant hypotension: marked drop in blood pressure leading to fainting. - Hyperkalemia: elevated potassium levels, potentially causing cardiac arrhythmias. - Severe skin reactions: such as Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor relevant parameters. - Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Renal function assessment: check serum creatinine and eGFR periodically. - Electrolyte surveillance: monitor potassium and sodium levels, especially in patients on other diuretics. - Hepatic impairment caution: dose adjustment may be required in severe liver disease. - Dehydration avoidance: correct fluid deficits before starting treatment. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use may increase risk of renal impairment. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): can blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - ACE inhibitors or other ARBs: additive blood‑pressure lowering effect may require dose adjustment. - Lithium: concomitant use can raise lithium concentrations, risking toxicity. - Antidiabetic agents: blood‑glucose control may improve, necessitating dose reevaluation.